MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Home・Aktien・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Geschlossen

BrancheGesundheitswesen

36.17 0.33

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.17

Max

36.17

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 51M
Verkäufe	39M 239M
KGV Branchendurchschnitt	12.073 90.831
EPS	1.08
Gewinnspanne	21.242
Angestellte	268
EBITDA	14M 73M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+20.79% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	517M 2.2B
Vorheriger Eröffnungskurs	35.84
Vorheriger Schlusskurs	36.17

Nachrichtenstimmung

By Acuity

58%

42%

310 / 361 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

29.8 / N/A Unterstützung & Widerstand

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Jan. 2026, 16:17 UTC

Akquisitionen, Fusionen, Übernahmen

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

19. Jan. 2026, 23:50 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

19. Jan. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

19. Jan. 2026, 22:29 UTC

Market Talk

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

19. Jan. 2026, 22:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

19. Jan. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

19. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. Jan. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

19. Jan. 2026, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

19. Jan. 2026, 17:09 UTC

Market Talk

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

19. Jan. 2026, 16:18 UTC

Market Talk

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

19. Jan. 2026, 16:12 UTC

Market Talk

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

19. Jan. 2026, 16:06 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

19. Jan. 2026, 16:04 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

19. Jan. 2026, 16:03 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH, CTG Duty-Free Also Entered Into a MoU

19. Jan. 2026, 16:02 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Subscription to Be Made Upon Completion of Transaction

19. Jan. 2026, 16:00 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

19. Jan. 2026, 16:00 UTC

Market Talk

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

19. Jan. 2026, 15:58 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

19. Jan. 2026, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

19. Jan. 2026, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Proceeds of Transaction Will Be Paid in Cash

19. Jan. 2026, 15:56 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

19. Jan. 2026, 15:53 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

19. Jan. 2026, 15:52 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

19. Jan. 2026, 15:51 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

19. Jan. 2026, 15:39 UTC

Market Talk

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

19. Jan. 2026, 15:37 UTC

Market Talk

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

20.79% Vorteil

12-Monats-Prognose

Durchschnitt 43.75 USD 20.79%

Hoch 55 USD

Tief 32 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Harmony Biosciences Holdings Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

310 / 361 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.